Although EGFR-TKIs have been demonstrated to be associated with improved ORR and PFS in advanced EGFR-mutant lung adenocarcinoma more than traditional chemotherapy regimens, the development of resistance to EGFR-TKIs typically occurs within 10–14 months after treatment initiation [2,14,15,16,17,18]. Here, EGFR is linked to lung adenocarcinoma.